Royalty Pharma (NASDAQ:RPRX) EVP George Lloyd Sells 79,346 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP George Lloyd sold 79,346 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $38.57, for a total value of $3,060,375.22. Following the completion of the sale, the executive vice president directly owned 30,654 shares of the company’s stock, valued at $1,182,324.78. The trade was a 72.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Royalty Pharma Trading Up 0.4%

NASDAQ:RPRX opened at $38.60 on Friday. The company has a market capitalization of $22.28 billion, a PE ratio of 29.24, a P/E/G ratio of 2.02 and a beta of 0.47. Royalty Pharma PLC has a 52-week low of $24.32 and a 52-week high of $41.24. The stock’s 50 day moving average price is $38.36 and its 200 day moving average price is $36.74. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. On average, research analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, November 14th. Royalty Pharma’s dividend payout ratio is presently 66.67%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. The Goldman Sachs Group initiated coverage on Royalty Pharma in a research report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price target on the stock. Weiss Ratings lowered Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Morgan Stanley decreased their price target on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. TD Cowen lifted their price objective on shares of Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Royalty Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $45.60.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RPRX. CWM LLC grew its stake in shares of Royalty Pharma by 1.5% during the 3rd quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 281 shares during the period. Augustine Asset Management Inc. grew its position in Royalty Pharma by 4.4% during the second quarter. Augustine Asset Management Inc. now owns 6,722 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 283 shares during the period. GAMMA Investing LLC increased its holdings in Royalty Pharma by 9.6% in the third quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 289 shares in the last quarter. Hudson Bay Capital Management LP lifted its position in shares of Royalty Pharma by 1.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after acquiring an additional 289 shares during the period. Finally, Merit Financial Group LLC boosted its stake in shares of Royalty Pharma by 3.5% during the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock worth $323,000 after acquiring an additional 306 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.